Surgeons and distributors from every continent engage with AdhFix in Rome
Bonevolent® AdhFix draws global clinical and commercial interest at the World Veterinary Orthopaedic Congress 2026.
One of the most striking moments of the week was the genuine, hands-on interest from surgeons and distributors representing all continents, wanting to bring the Bonevolent® AdhFix ecosystem into their operating theatres and their markets.
Engagement was particularly strong across Europe, Central and South America, Asia and the Middle East, with distributors and surgeons from these regions initiating concrete next steps toward clinical adoption and regional rollout. This truly global response confirms what we set out to build: a fixation solution that clinicians genuinely want to use, and that commercial partners see as a real opportunity to bring to their regions.
The conversations at our booth ranged from individual surgeons ready to adopt AdhFix in their own clinical practice, to distributors initiating discussions on regional rollout. In every case, the message was the same: the veterinary community is ready for a new generation of fracture fixation.
We came to WVOC expecting some traction for AdhFix, but the actual interest was well beyond my expectations. All our flyers disappeared already on the first day, and we had to print additional material locally in Rome to keep up with demand. That is a great sign of genuine community pull for the technology.” Prof. Michael Malkoch · CEO and Founder, Biomedical Bonding AB
As AdhFix now moves into the hands of more clinicians worldwide, every adopting surgeon will be onboarded through our structured training and certification pathway, ensuring the technology is delivered to patients at the highest standard of safety and outcome.
To every surgeon and distributor who reached out at WVOC: thank you. We are following up with each of you individually, and we look forward to welcoming you into the growing global AdhFix community.
Fractures aren’t standard. Neither is the care behind them.
Interested in AdhFix for your clinic or region?
Contact us at info@biomedicalbonding.com
Biomedical Bonding AB (BMB) is a Swedish medtech company developing Bonevolent®, a patented light-cured composite platform for metal-free bone fracture fixation. The Bonevolent® platform powers a family of products across veterinary and human applications, including AdhFix (veterinary), FRAP (human orthopaedics, preclinical), DendroPrime and Dentazine. BMB is headquartered in Stockholm, Sweden, and collaborates with leading academic and clinical institutions across Europe.
Learn more: www.biomedicalbonding.com
